key: cord-0871174-k087xhvp authors: Wang, Zhiren; Chen, Jiawei; Little, Nicholas; Lu, Jianqin title: Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery date: 2020-05-23 journal: Acta Biomater DOI: 10.1016/j.actbio.2020.05.026 sha: f51b776ec07597a3003dc4d6b2c654a50f4990ba doc_id: 871174 cord_uid: k087xhvp Abstract Self-assembling prodrugs represents a robust and effective nanotherapeutic approach for delivering poorly soluble anticancer drugs. With numerous intrinsic advantages, self-assembling prodrugs possess the maximum drug loading capacity, controlled drug release kinetics, prolonged blood circulation, and preferential tumor accumulation based on the enhanced permeability and retention (EPR) effect. These prodrug conjugates allow for efficient self-assembly into nanodrugs with the potential of encapsulating other therapeutic agents that have different molecular targets, enabling simultaneous temporal-spatial release of drugs for synergistic antitumor efficacy with reduced systemic side effects. The aim of this review is to summarize the recent progress of self-assembling prodrug cancer nanotherapeutics that are made through conjugating therapeutically active agents to Polyethylene glycol, Vitamin E, or drugs with different physicochemical properties via rational design, for synergistic tumor targeted drug delivery. In addition, it has been reported that, through rational design based on the unique physicochemical properties of different drugs, amphiphilic hydrophobic drug-hydrophilic drug conjugates can self-assemble into nanotherapeutics with enhanced bioavailability, improved PK and enhanced antitumor efficacy. [68] The merit of this design is that instead of physically loading other drugs inside various nanocarriers for combination cancer therapy, the drug-drug conjugate already contains two distinctly pharmaceutically active agents. Additionally, this amphiphilic drug-drug conjugation approach circumvents the nonuniform biodistribution of individual anticancer agents delivered through cocktail administration and ensures well-controlled temporal and spatial dual drug delivery vital for synergistic cancer elimination. [45, 46, 69, 70] In this review, we will emphasize the progress regarding the PEG-drug, VE-drug, and drug-drug-based SAP conjugates for targeted drug delivery for combination cancer therapy. Most of the nanocarrier components used in various drug delivery systems utilize "inert" excipients lacking any therapeutic activity. [46, 71] The presence of large amounts of carrier materials not only increases the overall therapy cost, but also gives rise to unwanted side effects. [72] One of the most sophisticated designs of drug delivery systems is that the components forming the carriers can also have therapeutic potential. Following the intracellular delivery, the bioactive component of the delivery carriers can be liberated and cooperate with co-delivered drugs for improved synergistic cancer therapy. [10] Combination therapy with two or more drugs in a single nanocarrier working simultaneously at different molecular signaling pathways can not only maximize the anticancer efficacy, but can also be conducive to overcome drug resistance and counteract the side effects developed by monotherapy. Herein, some of the recently developed SAP amphiphilic nanocarriers with hydrophobic backbone composed of lipophilic anticancer therapeutics are discussed. Embelin (EB) (Fig. 1A) is a naturally occurring alkyl-substituted hydroxyl benzoquinone compound and a major constituent of Embelia ribes BURM. It has been shown to possess hepatoprotective, anti-inflammatory, and antidiabetic effects. [73] In addition, EB also exhibits notable antitumor activity in various types of cancers by inhibiting the activity of X-linked inhibitor of apoptosis protein (XIAP). [74, 75] EB has negligible toxicity in normal cells and thereby presents a good safety profile, as XIAP is particularly overexpressed in various drug-resistant cancer cells with a minimal role in healthy cells. Hence, XIAP has been shown to be an effective target for selectively inhibiting cancer cell growth. [76, 77] Additionally through suppressing the NF-κB pathway, EB also has effects of downregulating the expression of several significant cancer promoting factors, such as XIAP, IAP1/2, survivin, cFLIP, TRAF1, Bcl-2 and Bcl-L. [75] However, owing to its long lipophilic acyl chain, EB is extremely hydrophobic, which renders poor aqueous solubility/bioavailability, unfavorable PK and unsatisfactory efficacy. To address the limitations associated with EB, we developed a series of PEG-dativized EB conjugates, which differ in PEG length and amount of EB, bridging through the aspartic acid-mediated labile ester bond (Fig. 1B) . Upon pegylation, the solubility of EB has been drastically increased from less than 1 mg/mL to more than 750 mg/mL. Equally important, PEG-EB conjugates retain similar cytotoxicity as the unmodified EB in three breast and prostate cancer cell lines. This effect is unlikely due to the polymer-drug conjugate surface activity as PEG-EB showed negligible hemolysis against red blood cells. More strikingly, PEG-EB prodrug not only self-assembles into spherical nanomicelles (~20 nm) in aqueous medium, but can also efficiently encapsulate other hydrophobic drugs such as PTX ( Fig. 1B) within its hydrophobic pocket to achieve synergistic cancer cell killing effect in four different breast and prostate cancer cell lines. This could be attributed to the efficient EB release from the conjugate following intracellular delivery, and consequently synergizing antitumor activity with PTX, which stabilizes the microtubes during mitosis. Moreover, we have demonstrated that the prodrug with two EB molecules and a longer PEG chain is markedly more effective for encapsulating PTX than the counterpart with a 1:1 PEG/EB molar ratio and a shorter PEG chain. [6, 58] This is upheld by the fact that PEG 5K -EB 2 (0.35 μM) had a much lower critical micelle concentration that that of PEG 3.5K -EB 2 (4.9 μM) and at the same carrier/PTX molar ratios, PEG 5K -EB 2 showed smaller particle size with lower polydispersity, higher drug loading, and improved formulation stability than PEG 3.5K -EB 2 . The strengthened formulation stability and drug loading in PEG 5K -EB 2 micelles is likely due to the improved PEG stealth effect, which exhibits greater steric hindrance. This prevents the ester linkage from being hydrolyzed under aqueous conditions, resulting in further stabilized micellar nanotherapeutics. Compared to the clinical PTX formulation, Taxol ® , the PTX/PEG 5K -EB 2 micellar formulation displayed a much slower and controlled PTX release as evidenced by the T 1/2 =34.1 h vs T 1/2 =6.57 h in Taxol ® . This delayed and more sustained PTX release from PEG 5K -EB 2 could be attributed to the strong interaction between the carriers and PTX. Additionally, EB has a benzoquinone ring and a long alkyl chain, which can form π-π stacking interactions and hydrogen bonding with PTX in addition to hydrophobic interactions, rendering enhanced overall carrier/PTX interaction. The close proximity of two EB lipidic chain in PEG 5K -EB 2 conjugate can facilitate the interaction of the carrier with PTX. Furthermore, PTX/PEG 5K -EB 2 presented a considerably higher maximum tolerated dose (MTD) as compared to Taxol (100 mg/kg vs 15 mg/kg), which is linked to slow release kinetics for PTX, lower nonspecific uptake by healthy organs, as well as the remarkable safety profile, in addition to the selectivity, anti-inflammatory and hepatoprotective activity of EB [6] . The increased MTD and enhanced safety allowed for maximal therapeutic efficacy to be achieved. In addition, PEG 5K -EB 2 was found to be capable of overcoming multi-drug resistance in NCI/ADR-RES cells through inhibiting the p-glycoprotein (P-gp) efflux pump. [10] Furthermore, near-infrared fluorescence (NIRF) imaging in prostate and lung cancer xenograft-bearing mice showed preferential tumor targeting for PEG 5K -EB 2 micelles ( Fig. 1C) . [6, 10] Most importantly, when compared to Taxol ® , the co-delivery of PTX by SAP PEG 5K -EB 2 micelles significantly enhanced tumor reduction in murine models of breast and prostate cancers with no noticeable systemic toxicities (Fig. 1D) . Consistent to literature, [64, 78, 79] through anchoring the folic acid (FA), a tumor specific targeting ligand, onto the surface of PEG 5K -EB 2 nanomicelles, the intratumoral accumulation was greatly enhanced, which led to further boosted tumor growth suppression.[10] The pegylated vitamin E (VE, Fig. 2A ), D-a-tocopheryl polyethylene glycol 1,000 (PEG 1K ) succinate (TPGS) system is another example of a dual functional nanocarrier. [80] [81] [82] VE, a lipophilic molecule with a long alkyl tail, is conjugated to PEG 1K through a biodegradable ester bond, allowing it to self-assemble into micelles with a hydrophobic pocket where water-insoluble drugs can be incorporated. It has been demonstrated that VE has an antitumor effect against a wide spectrum of cancers via various mechanisms including induction of apoptosis, inhibition of tumor cell proliferation and differentiation, suppression of nuclear factor-kappa B (NF-κB) activation, and so forth. [76, [82] [83] [84] [85] Due to its laudable functions as an emulsifier, solubilizer as well as a permeability and absorption enhancer, TPGS has been approved by the FDA as a safe pharmaceutical adjuvant for drug formulation. [81, 84, 86, 87] Additionally, based on its ability to inhibit P-glycoprotein (P-gp) drug efflux pumps, formulations with TPGS can reverse multidrug resistance (MDR) and improve the bioavailability of anticancer nanocarriers. [80, 82, 83, 88] Moreover, TPGS-based nanoformulations delivering PTX or other therapeutics exhibited potentiated antitumor activity in several animal cancer models. [81, 82] Nevertheless, the high critical micelle concentration (CMC) value (0.2 mg/mL), renders it unstable in vivo, and unable to serve as an effective nanocarrier to encapsulate therapeutics. [85] In order to improve this drug delivery system, we have developed a number of improved TPGS conjugates by varying the PEG length and altering the ratio of PEG and VE ( Fig. 2A) . Systemic structure and activity relationship study (SAR) demonstrated that all of the optimized prodrugs (PEG 2K -VE, PEG 2K -VE 2 , PEG 5K -VE, and PEG 5K -VE 2 ) retained the intrinsic activity of TPGS in inhibiting P-gp drug efflux pump. [80] Interestingly, PEG 5K -VE 2 outperformed other conjugates in terms of PTX drug loading and formulation stability, leading to the highest level of delaying tumor growth even in comparison to Taxol ® (FDA-approved PTX formulation). While PEG 5K -VE 2 performed best among the four systems, the drug loading capacity (DLC) is still not adequate and within a single digit. To further optimize this SAP system, a fluorenylmethyloxycarbonyl (Fmoc) drug-interactive motif was installed at the interfacial region of PEG 5K -VE 2 . [7] Fmoc has been shown to provide strong π−π stacking and hydrophobic interactions with other aromatic moieties, including itself (Fig. 2B) . [89] [90] [91] [92] To test this hypothesis, Doxorubicin (DOX) was chosen as the model drug since it has several aromatic rings. Upon Fmoc addition, PEG 5K -Fmoc-VE 2 can physically entrap up to 39.9% DOX, which was a drastic increase over the 2.9% DOX DLC for the PEG 5K -VE 2 , and also higher than most of the existing DOX nanoformulations. [7, 10, 60] Because of reinforced carrier/carrier and drug/carrier interactions, the Fmoc-embedded formulation improved the PK and MTD when delivering DOX in vivo through controlled and sustained drug release, resulting in a prominently increased tumor growth reduction over DOX/PEG 5K -VE 2 and Doxil ® (FDA-approved DOX nanoformulation) in breast, prostate, and drug-resistant murine cancer models (Fig. 2C ). In addition to EB and VE-based PEG SAP nanotherapeutic carriers, PEG-derived trans-farnesylthiosalicylic acid (FTS, Fig. 3 Most of the current approaches are centered on improving the nanocarriers in order to augment their compatibility with the therapeutic payloads. These strategies cannot accommodate some agents with complex chemical structures, such as camptothecin (CPT), despite working well for a number of anticancer drugs that have relatively simple structures. CPT, a potent chemotherapeutic, showed remarkable antineoplastic activity against a wide array of cancers by suppressing the topoisomerase I in the S-phase of the cell cycle during DNA replication. [99] However, owing to its extremely poor solubility, intrinsic instability (under physiologic conditions due to the involuntary conversion of the active lactone form to the inactive carboxylate form) and systemic toxicities, its clinical application has not been granted. Moreover, few of the existing nanocarriers can be formulated with this drug. Polymer derivatization strategy has been attempted to address these shortcomings, but have been met with limited success. This is likely attributed to ineffective drug release because of the considerable steric hindrance posed by macromolecular polymer. [100, 101] Instead of optimizing the nanocarrier component, we derivatized CPT with one molecule of VE, using either an ester bond or a disulfide linkage (Fig. 4A) . self-assembly into nanofibers with the stabilization of the PEG 5K -Fmoc-VE 2 -based nanomicellar carrier (Figs. 4B and 4C) . The formation of nanofibers of PEG 5K -Fmoc-VE 2 /CPT-VE and PEG 5K -Fmoc-VE 2 /CPT-S-S-VE, as compared to the spherical structures for PEG 5K -VE 2 /CPT, PEG 5K -Fmoc-VE 2 /CPT, PEG 5K -VE 2 /CPT-VE, PEG 5K -VE 2 /CPT-S-S-VE, and spherical shapes of the self-assembling prodrug described above, are likely due to strong π-π stacking interaction arisen from Fmoc moieties among carriers, Fmoc and aromatic rings in CPT and VE, and hydrophobic interactions between alkane chains among VEs between/among carriers and/or prodrugs as evidenced by the fluorescence quenching, UV absorbance, FT-IR, and NMR analysis. [9] CPT-S-S-VE showed significantly higher intracellular (Fig. 4D) and intratumoral drug release (Fig. 4F ) as compared to ester-bonded prodrug (CPT-VE) due to the high glutathione levels inside cancer cells and tumor tissue, [9, 46, 71, 102] which led to the higher anticancer activity both in vitro (Fig. 4E) and in vivo (Fig. 4G) . Both CPT prodrug nanofibers demonstrated greater efficacy over free CPT in curbing breast tumor development in the syngeneic mouse cancer models (Fig. 4G) . While the DLC for free CPT was only 0.65% when using the PEG 5K -Fmoc-VE 2 carrier, it was markedly increased to 9.2% for CPT-S-S-VE with improved formulation stability. This could be due to the fact that: 1) VE in prodrugs can function as a lipid anchor to facilitate its insertion/incorporation into the hydrophobic pocket formed by VE chains in nanocarrier; 2) the increased drug/carrier interactions such as π−π stacking between the Fmoc motif and the aromatic rings of CPT. [9] The VE-derivation has also been investigated for improving the compatibility of other common difficult-to-load drugs with existing carriers. It has been shown that DOX conjugated with D-a-tocopherol succinate (NDOX-TOS) formed a nanoassembly in aqueous solution after mixing with D-a-tocopherol poly(ethylene glycol) 2000 succinate with a much higher DOX DLC (34%) and led to superior tumor growth delay to free DOX. [67] Moreover, a recent discovery has demonstrated that PTX-conjugated VE, bridged via a disulfide linkage, led to spherical nanoparticles with improved PK and enhanced tumor killing effect in vivo as compared to Taxol ® . [103] This approach was realized by the hypothesis that the insertion of a single disulfide bond into hydrophobic molecules can balance the competition between intermolecular forces, resulting in the consequent nanotherapeutic self-assembly. In another approach to enhance the delivery of anticancer agents to tumor sites in the form of self-assembled nanotherapeutics, amphiphilic drug-drug conjugates (Ir) and the water insoluble drug, Chlorambucil (Cb) that self-assembled into spherical nanoparticle (Figs. 5A and 5B) . The authors demonstrated that the release of free Ir and free Cb was accelerated at weakly acidic environment, indicating potential hydrolysis in the tumor microenvironment. It was shown that the in vitro cytotoxicity of Ir-Cb ADCC was dependent on the critical aggregation concentration (CAC). When the concentration of Ir-Cb ADCC was lower than CAC, it did not produce any significant cytotoxicity. However, at concentration higher than CAC, Ir-Cb ADCC could produce significantly higher cytotoxicity compared to free Ir and A prodrug approach, particularly when they can self-assemble to form nano-sized drug delivery systems, is equipped with many advantages over parental drugs, such as and low pH). [67, 110] Additionally, the anticancer agents that either physically or covalently encapsulated to SAP systems ought to have different cancer molecular targets than those of the SAP's in order to realize the synergistic anticancer activity. Last but not least, to allow the efficient self-assembly into nanodrugs, the constructed prodrug conjugates must be amphiphilic. Apart from chemotherapeutic agents, the SAP platform can also be applied to other therapeutic modalities that have similar functional groups, such as tyrosine kinase inhibitors, corticosteroids, anti-inflammatory agents, immunomodulators, and drugs that target infectious diseases for improved therapeutic efficacy and reduced side effects. There are no conflicts of interest to declare. for the IV injection. *p < 0.01, compared to PEG 5K -Fmoc-VE 2 /CPT-S-S-VE (5 mg/kg); α p < 0.001, compared to PEG 5K -Fmoc-VE 2 /CPT-VE (5 mg/kg) and CPT (5 mg/kg); β p < 0.001, compared to saline. represented as average ± standard error. Statistical significance: **P < 0.005; ***P < 0.001. Polymeric micelles: nanocarriers for cancer-targeted drug delivery Nanocarriers as an emerging platform for cancer therapy Controlled drug delivery vehicles for cancer treatment and their performance Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come Micellar nanocarriers: pharmaceutical perspectives PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers An improved D-alpha-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance The battle of "nano" paclitaxel, Adv The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier Self-assembling prodrugs NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin Ring-opening polymerization of prodrugs: a versatile approach to prepare well-defined drug-loaded nanoparticles Poly(ethylene oxide)-block-polyphosphester-based Paclitaxel Conjugates as a Platform for Ultra-high Paclitaxel-loaded Multifunctional Nanoparticles Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy Self-assembly of block copolymers Rational design of "heat seeking" drug loaded polypeptide nanoparticles that thermally target solid tumors Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models Squalenoyl nanomedicines as potential therapeutics Kinetic trapping -a strategy for directing the self-assembly of unique functional nanostructures Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy Enzyme-instructed molecular self-assembly confers nanofibers and a supramolecular hydrogel of taxol derivative Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Enzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer Cells Building Nanostructures with Drugs Supramolecular nanostructures formed by anticancer drug assembly One-component nanomedicine Tuning Cellular Uptake of Molecular Probes by Rational Design of Their Assembly into Supramolecular Nanoprobes Multiwalled nanotubes formed by catanionic mixtures of drug amphiphiles Light-triggered, self-immolative nucleic Acid-drug nanostructures Amino acid sequence in constitutionally isomeric tetrapeptide amphiphiles dictates architecture of one-dimensional nanostructures One-Component Supramolecular Filament Hydrogels as Theranostic Label-Free Magnetic Resonance Imaging Agents Self-assembled Tat nanofibers as effective drug carrier and transporter Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment Cocktail Strategy Based on Spatio-Temporally Controlled Nano Device Improves Therapy of Breast Cancer Situ Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy A PEG-Fmoc conjugate as a nanocarrier for paclitaxel The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review Polymeric micelles for drug delivery Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer Block copolymer micelles: preparation, characterization and application in drug delivery Dual-function nanocarriers with interfacial drug-interactive motifs for improved delivery of chemotherapeutic agents PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer Fmoc-conjugated PEG-vitamin E2 micelles for tumor-targeted delivery of paclitaxel: enhanced drug-carrier interaction and loading capacity Formulation of Docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy Functionalized micellar systems for cancer targeted drug delivery Diacyllipid-Polymer Micelles as Nanocarriers for Poorly Soluble Anticancer Drugs Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity Self-Assembly of an Amphiphilic Janus Camptothecin-Floxuridine Conjugate into Liposome-Like Nanocapsules for More Efficacious Combination Chemotherapy in Cancer Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate Supramolecular Polymer-Based Nanomedicine: High Therapeutic Performance and Negligible Long-Term Immunotoxicity Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models Antitumor, anti-inflammatory and analgesic property of embelin, a plant product Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias XIAP: apoptotic brake and promising therapeutic target Avidity mechanism of dendrimer-folic acid conjugates Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®) Vitamin E TPGS as a molecular biomaterial for drug delivery Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells Paclitaxel nanocrystals for overcoming multidrug resistance in cancer Advances in the use of tocols as drug delivery vehicles Nanostructured Hydrogels for Three-Dimensional Cell Culture Through Self-Assembly of Fluorenylmethoxycarbonyl-Dipeptides Supramolecular hydrogels respond to ligand-receptor interaction Self-Assembled Hydrogel Composed of a Modified Aromatic Dipeptide Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier Dislodgment and accelerated degradation of Ras Ras-dependent cell growth by farnesylthiosalisylic acid Tailoring Ras-pathway--inhibitor combinations for cancer therapy RAS inhibitors: potential for cancer therapeutics The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel Cancer therapies utilizing the camptothecins: a review of the in vivo literature Polymer-bound camptothecin: initial biodistribution and antitumour activity studies Disulfide cross-linked phosphorylcholine micelles for triggered release of camptothecin Glutathione levels in human tumors Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines Rational Design of a New Self-Codelivery System from Redox-Sensitive Camptothecin-Cytarabine Conjugate Assembly for Effectively Synergistic Anticancer Therapy Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy Methotrexate-Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy Self-Assembly of Drug-Drug Conjugates as Drug Self-Delivery System for Tumor-Specific pH-Triggered Release Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy Multifunctional stable and pH-responsive polymer vesicles formed by heterofunctional triblock copolymer for targeted anticancer drug delivery and ultrasensitive MR imaging 5K -EB 2 , and PEG 5K -EB 2 . (B) Schematic illustration of self-assembling PEG-EB 2 prodrug conjugate with Paclitaxel loaded inside. (C) In vivo NIRF optical imaging of CL1 lung tumor-bearing SCID mice after intravenous (IV) injection of free DiR dye and DiR-loaded PEG 5K -EB 2 micelles. (D) Improved anticancer efficacy of PTX formulated in PEG 5K -EB 2 micelles in nude mice-bearing PC-3 prostate tumors cells/mouse subcutaneously, mice were IV administered with different treatments on days 1, 3, 7, 10, 13, 24, and 28, and relative tumor volume was mg/kg PTX/PEG 5K -EB 2 vs Reproduced with permission from PEG 5K -FTS 2 (L, labile), and PEG 5K -FTS 2 (S, Stable) This work was supported in part by a Startup Fund from the College of Pharmacy and two COVID-19 Rapid Turn-Around Seed Grants from the BIO5 Institute at The University of Arizona, and by NIH grants P30 ES006694 and R35 ES031575.